23 nov: Aktier/åbning: Indekstunge aktier trækker eliteindeks i rødt
23 nov: Danmark/økonomer: Ledighedstal tegner dystert billede
23-11-2016 10:06:12

Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

Relateret indhold
10 aug - 
Bavarian-partner tegner nye aktier til 405 kr. i udvide..
28 jul - 
Fredagens aktier: Lundbeck blev tynget af tysk skepsis
28 jul - 
Aktier/middag: Kun Novo Nordisk undgår depressiv stemni..
Relateret debat
09:49 - 
Jeg synes vi hænger fast her ved kurs 400. Mon ik..
08:03 - 
Artiklen er indsendt Nov 2016.    Tidligere h..
06:54 - 
Jeg fandt denne men fatter hat. Desværre ikke nogen kon..

COPENHAGEN, Denmark, November 23, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company's share capital has been increased by nominally DKK 4,197,860 as a consequence of employees' exercise of warrants.

The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. The shares were subscribed for in cash at the following prices per share of nominally DKK 10: 286,283 shares at DKK 73.90 and 133,503 shares at DKK 59.10. The total proceeds to Bavarian Nordic A/S from the capital increase amounts to DKK 29 million.

The new shares, which will rank pari passu in all respects with existing Bavarian Nordic shares, will be admitted to trading and official listing on Nasdaq Copenhagen as soon as possible.

Pursuant to section 10 of Executive Order no. 1258 of November 9, 2015 on Issuers' Disclosure Obligations, it is hereby announced, that the total nominal value of Bavarian Nordic A/S' share capital after the capital increase is DKK 313,538,460, which is made up of 31,353,846 shares of a nominal value of DKK 10 each, corresponding to 31,353,846 votes.

The revised Articles of Association will be published separately and will subsequently be available on the Company's website.

The content of this announcement does not affect the Company's expectations for the financial results for 2016.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

Company Announcement no. 29 / 2016

2016-29-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 771532.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
16 aug
BAVA
Kære Bavarian aktionærer jeg har forsøgt at samle lidt informationer sammen dels taget fra ”sodazare..
23
12 aug
BAVA
Tak til hr. Baronen for et seriøst indlæg. Jeg har Bavarian, men er nok endnu ikke klar til at begyn..
8
15 aug
BAVA
Tror de fleste seriøse investorer herinde er ret ligeglade med jeres handler, men hvad med I skriver..
6
15 aug
BAVA
Ved lejlighed kunne du jo lige poste en af dine "store" transaktioner, bare antallet...Det virker så..
6
14 aug
BAVA
Speedfires indlæg længere nede, med linket til den bms ansatte er egentligt meget interresant. Han b..
6
15 aug
BAVA
Umiddelbart positiv læsning for Bavarian, idet Bavarian's middel  har en anden tilgang til RSV. Men ..
5
12 aug
BAVA
Det bedste lige pt er tænke kort og tænke swing når det kommer til bava i disse usikre tider især fo..
5
15 aug
BAVA
Men du kan ikke slå Baronen, han køber under laveste kurs, der må vi andre give op
4
14 aug
BAVA
Der er regnskab i næste uge den 25/8 - lige vedlagte en kilde jeg har fundet i aften som optaler mar..
4
13 aug
BAVA
Jeg vil gerne ønske alle helt og lykke med deres strategi: Daytraderne med deres sving gevinster ..
4

Aktier/åbning: Novo tager bundplacering i rødt marked

18-08-2017 09:18:37
Det danske C20 Cap-indeks fortsætter de negative tendenser fra USA og Asien og åbner med et fald på 0,6 pct. i et overvejende rødt marked, hvor særligt Novo Nordisk skiller sig negativt ud.Eliteindekset følger altså uroen fra de tre store amerikanske aktieindeks, Dow Jones, S&P 500 og Nasdaq, som torsdag dykkede markant for anden gang på tre dage, samt de asiatiske markeder, der ligeledes overveje..

Aktier/tendens: Fald i vente efter terror og Trump-tvivl

18-08-2017 08:17:03
På en fredag med få regnskaber lugter det af fald på det danske aktiemarked, efter de amerikanske børser torsdag løb ind i en større nedtur, som fredag også viser sig i Asien.De tre store amerikanske aktieindeks, Dow Jones, S&P 500 og Nasdaq, dykkede torsdag markant for anden gang på blot tre dage og endte med fald i intervallet 1,2-1,9 pct. efter tvivl om Donald Trumps evne til at gennemføre de l..

MT Højgaard leverer fremgang trods omkostninger til offshoresag

17-08-2017 15:39:35
Entreprenørselskabet MT Højgaard, der ejes 46 pct. af børsnoterede Monberg & Thorsen og 54 pct. af Højgaard Holding, leverede fremgang i andet kvartal trods særlige omkostninger til en tabt sag om vindmøllefundamenter, som koncernen tidligere har oplyst om.Omsætningen steg til 1931 mio. kr. fra 1605 mio. kr. i samme kvartal året før, mens EBIT før særlige poster landede på 63 mio. mod minus 5 mio...

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Fald i vente efter terror og Trump-tvivl
2
Torsdagens aktier: GN trak stikket hjem - ISS og Vestas helt i bund
3
Aktier/åbning: Novo tager bundplacering i rødt marked
4
ECB-medlemmer bekymret: Eurostyrkelse kan stikke af
5
Efter våd sommer: Nu er højsæsonen for dårlige afkast over os

Relaterede aktiekurser

Bavarian Nordic A/S 400,50 -0,6% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. august 2017 12:53:06
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170808.1 - EUROWEB6 - 2017-08-18 12:53:06 - 2017-08-18 12:53:06 - 1 - Website: OKAY